Literature DB >> 24357720

FGF2-induced Ras-MAPK signalling maintains lymphatic endothelial cell identity by upregulating endothelial-cell-specific gene expression and suppressing TGFβ signalling through Smad2.

Taeko Ichise1, Nobuaki Yoshida, Hirotake Ichise.   

Abstract

The lymphatic endothelial cell (LEC) fate decision program during development has been described. However, the mechanism underlying the maintenance of differentiated LEC identity remains largely unknown. Here, we show that fibroblast growth factor 2 (FGF2) plays a fundamental role in maintaining a differentiated LEC trait. In addition to demonstrating the appearance of LECs expressing α-smooth muscle actin in mouse lymphedematous skin in vivo, we found that mouse immortalised LECs lose their characteristics and undergo endothelial-to-mesenchymal transition (EndMT) when cultured in FGF2-depleted medium. FGF2 depletion acted synergistically with transforming growth factor (TGF) β to induce EndMT. We also found that H-Ras-overexpressing LECs were resistant to EndMT. Activation of H-Ras not only upregulated FGF2-induced activation of the Erk mitogen activated protein kinases (MAPK3 and MAPK1), but also suppressed TGFβ-induced activation of Smad2 by modulating Smad2 phosphorylation by MAPKs. These results suggest that FGF2 regulates LEC-specific gene expression and suppresses TGFβ signalling in LECs through Smad2 in a Ras-MAPK-dependent manner. Taken together, our findings provide a new insight into the FGF2-Ras-MAPK-dependent mechanism that maintains and modulates the LEC trait.

Entities:  

Keywords:  Endothelial–mesenchymal transition; FGF2; Lymphatic endothelial cell; MAPK; Ras; Smad

Mesh:

Substances:

Year:  2013        PMID: 24357720     DOI: 10.1242/jcs.137836

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  25 in total

1.  Tumor Endothelial Cells with Distinct Patterns of TGFβ-Driven Endothelial-to-Mesenchymal Transition.

Authors:  Lin Xiao; Dae Joong Kim; Clayton L Davis; James V McCann; James M Dunleavey; Alissa K Vanderlinden; Nuo Xu; Samantha G Pattenden; Stephen V Frye; Xia Xu; Mark Onaitis; Elizabeth Monaghan-Benson; Keith Burridge; Andrew C Dudley
Journal:  Cancer Res       Date:  2015-01-29       Impact factor: 12.701

2.  Mesenchymal status of lymphatic endothelial cell: enlightening treatment of lymphatic malformation.

Authors:  Xu Cai; Wei Zhang; Gang Chen; Rui-Fang Li; Yan-Fang Sun; Yi-Fang Zhao
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 3.  Fine-tuning vascular fate during endothelial-mesenchymal transition.

Authors:  Lin Xiao; Andrew C Dudley
Journal:  J Pathol       Date:  2016-11-10       Impact factor: 7.996

Review 4.  Receptor tyrosine kinases endocytosis in endothelium: biology and signaling.

Authors:  Xi Zhang; Michael Simons
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-06-12       Impact factor: 8.311

Review 5.  Endothelial to Mesenchymal Transition in Cardiovascular Disease: JACC State-of-the-Art Review.

Authors:  Jason C Kovacic; Stefanie Dimmeler; Richard P Harvey; Toren Finkel; Elena Aikawa; Guido Krenning; Andrew H Baker
Journal:  J Am Coll Cardiol       Date:  2019-01-22       Impact factor: 24.094

Review 6.  Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases.

Authors:  Sonsoles Piera-Velazquez; Sergio A Jimenez
Journal:  Physiol Rev       Date:  2019-04-01       Impact factor: 37.312

7.  Aligned nanofibrillar collagen scaffolds - Guiding lymphangiogenesis for treatment of acquired lymphedema.

Authors:  Stanley G Rockson; John P Cooke; Ngan F Huang; Catarina Hadamitzky; Tatiana S Zaitseva; Magdalena Bazalova-Carter; Michael V Paukshto; Luqia Hou; Zachary Strassberg; James Ferguson; Yuka Matsuura; Rajesh Dash; Phillip C Yang; Shura Kretchetov; Peter M Vogt
Journal:  Biomaterials       Date:  2016-06-07       Impact factor: 12.479

8.  FGF2-mediated attenuation of myofibroblast activation is modulated by distinct MAPK signaling pathways in human dermal fibroblasts.

Authors:  David M Dolivo; Sara A Larson; Tanja Dominko
Journal:  J Dermatol Sci       Date:  2017-09-01       Impact factor: 4.563

Review 9.  Fibroblast growth factor-transforming growth factor beta dialogues, endothelial cell to mesenchymal transition, and atherosclerosis.

Authors:  Pei-Yu Chen; Michael Simons
Journal:  Curr Opin Lipidol       Date:  2018-10       Impact factor: 4.776

Review 10.  Fibroblast Growth Factor 2 as an Antifibrotic: Antagonism of Myofibroblast Differentiation and Suppression of Pro-Fibrotic Gene Expression.

Authors:  David M Dolivo; Sara A Larson; Tanja Dominko
Journal:  Cytokine Growth Factor Rev       Date:  2017-09-23       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.